RSS Facebook Twitter YouTube

Immunotherapy exhibits antileukemic activity

New Articles

ALL-BCP_vashi-donsk-230.jpg
B-cell precursor ALL
Image by Vashi Donsk

Blinatumomab has demonstrated activity in high-risk patients with Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to research published in the Journal of Clinical Oncology. This phase 2 trial enrolled patients with relapsed or refractory Ph+ BCP-ALL who had failed treatment with at least 1 tyrosine kinase inhibitor (TKI). Blinatumomab produced a complete response (CR) in 31% of these patients . . . [Read Article]